文献速递其他结缔组织病

来氟米特联合羟氯喹治疗原发干燥综合征的随机对照试验

Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
PubMed 文献 · Lancet Rheumatol · 2020-03-26

这项安慰剂对照双盲2A期随机试验纳入29例ESSDAI≥5且唇腺活检灶性评分≥1的原发干燥综合征患者,以来氟米特20mg联合羟氯喹400mg每日治疗24周。

要点

  • 来氟米特联合羟氯喹治疗24周可显著降低原发干燥综合征患者ESSDAI评分。
  • 联合组未发生严重不良事件,安慰剂组发生2例严重不良事件。
  • 联合组胃肠道不适和丙氨酸氨基转移酶短暂升高较安慰剂组更常见。

核心结论

  • 来氟米特联合羟氯喹治疗原发干燥综合征安全,并产生临床应答。
  • 结果值得在更大规模临床试验中进一步评估该联合方案。

研究设计与样本

  • 在荷兰乌得勒支大学医学中心开展的安慰剂对照、双盲、2A期随机临床试验。
  • 纳入29例18-75岁、ESSDAI评分≥5且唇腺活检灶性评分≥1的原发干燥综合征患者。
  • 按2:1随机分配接受来氟米特20mg联合羟氯喹400mg每日或安慰剂治疗24周。
  • 主要终点为0至24周ESSDAI评分变化组间差异,校正基线ESSDAI评分,按意向治疗分析。

主要发现

  • 共筛查37例患者,纳入29例(28例女性,1例男性),联合组21例,安慰剂组8例。
  • 安慰剂组1例因第13周需大剂量泼尼松治疗风湿性多肌痛被排除出主要分析。
  • 联合组无严重不良事件,安慰剂组发生2例严重不良事件(胰腺炎住院和肾结石住院)。

关键数值与推荐

  • 入组标准:年龄18-75岁、ESSDAI评分≥5、唇腺活检灶性评分≥1。
  • 干预方案:来氟米特20mg联合羟氯喹400mg每日,治疗24周。

临床怎么用

  • 对于ESSDAI评分≥5且唇腺活检灶性评分≥1的原发干燥综合征患者,来氟米特联合羟氯喹可能降低疾病活动度。
  • 治疗期间需关注胃肠道不适和丙氨酸氨基转移酶短暂升高。
  • 该联合方案的安全性需在更大规模试验中进一步确认。

局限性

  • 样本量较小,联合组21例、安慰剂组8例。
  • 为2A期单中心试验,结果需在更大规模临床试验中验证。
  • 安慰剂组1例因合并风湿性多肌痛使用大剂量泼尼松被排除出主要分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary Sjögren's syndrome is a systemic autoimmune disease characterised by secretory gland dysfunction, for which no effective therapy is available. Based on the complementary properties of leflunomide and hydroxychloroquine in inhibiting activation of key immune cells in primary Sjögren's syndrome, we aimed to evaluate the clinical efficacy and safety of leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome. METHODS: We did a placebo-controlled, double-blinded, phase 2A randomised clinical trial in patients with primary Sjögren's syndrome at the University Medical Center Utrecht (Utrecht, Netherlands). Eligible patients were aged 18-75 years, had a European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI) score of 5 or higher, and a lymphocytic focus score of 1 or higher in labial salivary gland biopsy specimens. Patients were randomly assigned (2:1) with block randomisation (block size of six) to receive leflunomide 20 mg and hydroxychloroquine 400 mg daily or placebo for 24 weeks. The primary endpoint was the between-group difference in change in ESSDAI scores from 0 to 24 weeks, adjusted for baseline ESSDAI score. Patients were analysed according to the intention-to-treat principle. This study is registered with EudraCT, 2014-003140-12. FINDINGS: Between March 7, 2016, and Nov 30, 2017, 37 patients were screened, of whom 29 patients (28 women and one man) were enrolled. 21 patients were assigned to receive leflunomide-hydroxychloroquine and eight patients were assigned to receive placebo. One patient in the placebo group required high-dose prednisone to treat polymyalgia rheumatica at week 13 and was excluded from the primary analysis. From 0 to 24 weeks, the mean difference in ESSDAI score, adjusted for baseline values, in the leflunomide-hydroxychloroquine group compared with the placebo group was -4·35 points (95% CI -7·45 to -1·25, p=0·0078). No serious adverse events occurred in the leflunomide-hydroxychloroquine group and two serious adverse events occurred in the placebo group (hospital admission for pancreatitis and hospital admission for nephrolithiasis). The most common adverse events in the leflunomide-hydroxychloroquine group were gastrointestinal discomfort (11 patients [52%] vs two [25%] in the placebo group), modest transient increases in alanine aminotransferase (ten [48%] vs one [13%]), and short episodes of general malaise and shivering (nine [43%] vs one [13%]). INTERPRETATION: Leflunomide-hydroxychloroquine was safe and resulted in a clinical response in patients with primary Sjögren's syndrome. These results warrant further evaluation of leflunomide-hydroxychloroquine combination therapy in larger clinical trials. FUNDING: ZonMw.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. van der Heijden EHM, Blokland SLM, Hillen MR, et al. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol. 2020. PMID: 38273473. doi:10.1016/S2665-9913(20)30057-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。